- Home
- MYD vs LAB Comparison
MYD vs LAB Comparison
Compare MYD & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYD
- LAB
- Stock Information
- Founded
- MYD 1991
- LAB 1999
- Country
- MYD United States
- LAB United States
- Employees
- MYD N/A
- LAB N/A
- Industry
- MYD Investment Bankers/Brokers/Service
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- MYD Finance
- LAB Industrials
- Exchange
- MYD Nasdaq
- LAB Nasdaq
- Market Cap
- MYD 523.6M
- LAB 562.1M
- IPO Year
- MYD N/A
- LAB 2011
- Fundamental
- Price
- MYD $11.14
- LAB $1.66
- Analyst Decision
- MYD
- LAB Strong Buy
- Analyst Count
- MYD 0
- LAB 2
- Target Price
- MYD N/A
- LAB $2.88
- AVG Volume (30 Days)
- MYD 253.1K
- LAB 2.7M
- Earning Date
- MYD 01-01-0001
- LAB 10-30-2024
- Dividend Yield
- MYD 4.55%
- LAB N/A
- EPS Growth
- MYD N/A
- LAB N/A
- EPS
- MYD N/A
- LAB N/A
- Revenue
- MYD N/A
- LAB $155,902,000.00
- Revenue This Year
- MYD N/A
- LAB $62.60
- Revenue Next Year
- MYD N/A
- LAB $9.91
- P/E Ratio
- MYD N/A
- LAB N/A
- Revenue Growth
- MYD N/A
- LAB 48.23
- 52 Week Low
- MYD $8.76
- LAB $1.21
- 52 Week High
- MYD $11.30
- LAB $3.04
- Technical
- Relative Strength Index (RSI)
- MYD 45.57
- LAB 37.68
- Support Level
- MYD $11.09
- LAB $1.46
- Resistance Level
- MYD $11.23
- LAB $1.69
- Average True Range (ATR)
- MYD 0.10
- LAB 0.15
- MACD
- MYD 0.01
- LAB -0.06
- Stochastic Oscillator
- MYD 47.22
- LAB 13.37
About MYD Blackrock MuniYield Fund Inc.
Blackrock Muniyield Fund Inc is a non-diversified, closed-end management investment company. The fund's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.